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serum as potential markers for detecting
hepatocellular carcinoma: a retrospective
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ABSTRACT
Objective: Serum a-fetoprotein (AFP) is the most
commonly used biomarker for screening
hepatocellular carcinoma (HCC) but fails to detect
about half of the patients. Thus, we investigated if
circulating microRNAs (miRNAs) could outperform
AFP for HCC detection.
Design: A retrospective cohort study.
Setting: Two clinical centres in China.
Participants: The exploration phase included 96
patients with HCC who received primary curative
hepatectomy, and the validation phase included 29
hepatitis B carriers, 57 patients with HCC and 30
healthy controls.
Main outcome measures: Expression of
miRNAs was measured by real-time quantitative
reverse transcriptionePCR. Areas under receiver
operating characteristic curves were used to
determine the feasibility of using serum miRNA
concentration as a diagnostic marker for defining
HCC. A multivariate logistic regression analysis was
used to evaluate performances of combined serum
miRNAs.
Results: In the exploration phase, miRNA profiling on
resected tumour/adjacent non-tumour tissues
identified miR-15b, miR-21, miR-130b and miR-183
highly expressed in tumours. These miRNAs were also
detectable in culture supernatants of HCC cell lines and
in serum samples of patients. Remarkably, these
serum miRNAs were markedly reduced after surgery,
indicating the tumour-derived source of these
circulating miRNAs. In a cross-centre validation study,
combined miR-15b and miR-130b demonstrated as
a classifier for HCC detection, yielding a receiver
operating characteristic curve area of 0.98 (98.2%
sensitivity and 91.5% specificity). The detection
sensitivity of the classifier in a subgroup of HCCs with
low AFP (<20 ng/ml) was 96.7%. The classifier also
identified early-stage HCC cases that could not be
detected by AFP.
Conclusion: The combined miR-15b and miR-130b
classifier is a serum biomarker with clinical value for
HCC screening.
INTRODUCTION
Hepatocellular carcinoma (HCC) is the most
common type of malignancy of liver cancer,
with high incidences (>500 000 cases per
year) in hepatitis B virus (HBV) endemic
ARTICLE SUMMARY
Article focus
- More than half of the patients with HCC are not
eligible for curative treatments because of the
advanced tumour stages at the time of diagnosis.
- Serum AFP has long been used as a biomarker
for HCC screening, but its sensitivity and
accuracy are only modest.
- Circulating miRNAs are highly stable in blood and
have a potential to become promising cancer
biomarkers.
Key messages
- This study identifies combined serum miR-15b
and miR-130b as a classifier that provides high
sensitivity and accuracy for detection of HCC.
- The classifier outperformed AFP in discriminating
HCC cases from non-cancerous controls. In
addition, it identified early-stage HCC cases that
could not be detected by AFP.
- These findings collectively suggest that the
miRNA classifier has clinical value and might
be used for HCC screening programme, which
could increase chances of patients with HCC for
curative treatments.
Strengths and limitations of this study
- The proposed classifier has been validated in an
independent cohort of serum samples that
includes patients with HCC, chronic hepatitis B
carriers and healthy controls, suggesting the
high positive predictive rate of the circulating
miRNA classifier, and could be used as non-
invasive biomarkers for HCC.
- Other variables may affect the diagnostic accu-
racy of the classifier, for example, the presence
of hepatitis C virus, which is also a risk factor for
HCC. The application of the classifier in hepatitis
C virus-related HCC is yet to be validated.
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regions, including China, Southeast Asia and sub-Sahara
Africa.1 2 HCC is also highly malignant and lethal, with an
overall 5-year survival rate of 5%e9% from the time of
clinical diagnosis. The dismal prognosis is largely caused
by late detection of the tumours when standard surgery is
not operable, high recurrence rate of the malignancy and
resistance to chemotherapy.3 4 Approximately 80% of
patients with HCC are untreatable because of advanced
tumour stages at presentation; nevertheless, curative
hepatectomy can improve the 5-year survival rate to 69%
if the tumour is detected earlier, particularly when the
tumour is single nodule and smaller than 2 cm.5 6
Diagnosis of HCC is usually based on imaging tech-
niques (abdominal ultrasound, MRI and contrast-
enhanced CT scan showing a suspicious liver lesion),
elevated serum a-fetoprotein (AFP) or optional biopsy.
Advances in MRI and CT scan have greatly improved
imaging of focal hypervascular mass consistent with
HCC, but these procedures are costly and not readily
available in developing countries. Ultrasonography
can detect large lesion but fails to detect small
tumour, especially in obese patients and those with
underlying liver cirrhosis; and the procedures are
operator-dependent, varying the diagnostic accuracy.
Serum AFP has long been used as a tumour marker for
HCC screeningdAFP <20 ng/ml is considered as
normal and AFP >400 ng/ml as true positive in general.
The European Society for Medical Oncology (EMSO)
guidelines also recommended that elevation of AFP
>400 ng/ml can be used instead of fine-needle cytology
for diagnosis, especially in patients with liver cirrhosis.7
Despite that, the sensitivity of AFP is only modest
(sensitivity: 39%e65% and specificity: 76%e94%),
leaving approximate one-third of the patients with early-
stage HCC with small tumours (<3 cm) undiagnosed.8
On the other hand, serum AFP level is elevated in
benign liver diseases, such as hepatitis and cirrhosis.9
Thus, there is still pressing need for circulating
biomarkers to detect early HCC in at-risk populations
(patients with chronic hepatitis and/or liver cirrhosis).
MicroRNAs (miRNAs) are a class of non-coding small
RNAs that regulate expression of genes at post-transcrip-
tional level. They are involved in various biological
processes, including development, differentiation, signal
transduction and carcinogenesis.10 11 The use ofmiRNAas
cancer biomarker is of particular interest because (1)
different cancer types have distinct miRNA expression
profiles12;(2) cancers could affect miRNA levels in the
bloodstream,13 although the exact mechanisms through
which the miRNAs are being released extracellularly
remain unclear and (3) miRNAs could be detected in
bloodplasmaor serumwithhigh stability.13 14They arewell
protected from RNases and remain stable after harsh
conditions. To explore the clinical applicability ofmiRNAs
asnon-invasive circulatingHCCbiomarker,we investigated
the expression profile of miRNAs in tumour tissues and
selected candidate miRNA biomarkers. These biomarkers
were evaluated in a set of serum samples from the same
patient cohort. Last but not least, we further validated the
miRNAbiomarkers for detectingHCC in a separate cohort
of serum samples from another clinical centre.
PATIENTS AND METHODS
Patients
Figure 1 shows the schematic flow chart for this miRNA
biomarker discovery study. We first profiled 220 miRNAs
using real-time quantitative PCR (qPCR) on frozen
tumour and matched adjacent non-tumour tissues from
96 Chinese patients with HCC who received primary
curative hepatectomy at QueenMaryHospital (Pokfulam,
Hong Kong) between 1990 and 2007.15e17 Among this
cohort, we identified 15 patients with HCC having suffi-
cient amount of matched serum samples collected before
and after surgery to allow us measuring the selected
miRNAs levels by qPCR. The preoperative serum samples
were collected from 1 to 4 days before surgery, whereas
the postoperative serum samples were collected from 8 to
359 days after surgery. The Institutional Review Board of
the University of Hong Kong/Hospital Authority Hong
Kong West Cluster approved this study, and each patient
gave his/her written informed consent on the use of the
clinical specimens for research.
For the validation study, we obtained 116 serum
samples from Chang Zheng Hospital and Eastern
Hepatobiliary Surgery Hospital (Shanghai, China),
which included 29 hepatitis B carriers, 57 patients
Figure 1 Schematic flow chart of microRNA (miRNA)
biomarker discovery for detecting hepatocellular carcinoma
(HCC). This study was divided into three phases: exploration,
selection/filtering and cross-centre validation. Two different
cohorts of patients were includeddone from Hong Kong
(n¼96) and one from Shanghai (n¼116).
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with HCC and 30 healthy controls who underwent
routine physical examinations with no underlying liver
diseases. The hepatitis B carriers were individuals with
positive serum hepatitis B surface antigen for at least
6 months at the time of blood collection, and they had
previously shown normal (or minimally raised) levels of
liver enzymes and negative for hepatitis B surface
antigen. The clinicalepathological characteristics of the
participants are summarised in table 1.
Cell lines
Liver cell lines (MIHA, CL-48, HepG2, Hep3B, PLC/
PRF/5 and MHCC-97H) were obtained as previously
described.18 19 Cells were grown in Dulbecco’s modified
Eagle’s medium (HyClone, Logan, Utah, USA) supple-
mented with 10% fetal bovine serum at 378C in a 5% CO2
incubator. Upon confluence, media were collected and
spun at 1200 g for 3 min to remove living cells before
RNA extraction.
Samples processing and miRNA extraction
Total RNAs were extracted from frozen liver tissues using
TRIzol (Invitrogen, Carlsbad, California, USA) as
previously described.15 Blood samples were stored with
EDTA, and serum specimens were stored at 808C until
use. Total RNAs from serum samples or cell culture
media were extracted using TRIzol LS (Invitrogen).
Each of the 500 ml of sera or media was added with 1 ml
of TRIzol LS and then added with 200 ml chloroform.
One volume of the aqueous layer was precipitated with
1.5 volumes of absolute ethanol, and the mixture was
transferred to RNeasy Mini spin column (Qiagen,
Hilden, Germany) for purification according to the
manufacturer’s instructions. Each sample was eluted
with 30 ml RNase-free water. The concentrations of RNA
extracted from the clinical samples ranged from 3.96 to
41.95 ng/ml.
miRNA quantification by real-time qPCR
miRNAs from tumour and adjacent non-tumour tissues
were profiled using custom qPCR assays as described.15
The profiling data are available in Gene Expression
Omnibus, under accession number GSE22058.
Expressions of the potential miRNA biomarkers were
quantified in serum samples and HCC cell-conditioned
media by TaqMan miRNA Assay (Applied Biosystems,
Table 1 Demographic and clinicopathologic parameters of patients from different cohorts
Parameters
Hong Kong cohort (n[96) Shanghai cohort (n[116)
Patients with HCC Healthy controls Hepatitis B carriers Patients with HCC
Sex
Male 78 22 20 49
Female 18 8 9 8
Age (years)
<60 60 30 28 47
$60 36 0 1 10
a-fetoprotein (ng/ml)
<20 39 e 29 30
20e400 26 e 0 16
>400 31 e 0 11
Alanine aminotransferase (U/l)
<35 28 e 20 29
$35 68 e 9 28
Aspartate aminotransferase (U/l)#
<35 23 e 21 24
$35 73 e 4 33
Hepatitis B surface antigen
Negative 12 e 0 0
Positive 84 e 29 57
Pathological tumour-node-metastasis stage*
Early (I, II) 41 e e 45
Late (III, IV) 55 e e 11
ChildePughy
A 91 e e 54
B 3 e e 2
C 0 e e 0
Tumour size (cm)*
<5 26 e e 27
$5 70 e e 29
*Data indicated in the cohort from Shanghai are based on 56 cases.
yData indicated in the cohorts from Hong Kong and Shanghai are based on 94 and 56 cases, respectively.
HCC, hepatocellular carcinoma.
#Data indicated in the Shanghai cohort are based on 25 hepatitis B carriers.
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Figure 2 (A) Hierarchical clustering (centred correlation and average linkage) over 105 differentially expressed microRNAs (miRNAs).
Heat map colours represent the relative miRNA expression as indicated in the colour key. (B) Expressions of the candidate miRNA
biomarkers in hepatocellular carcinoma tumour (TU) and adjacent non-tumour (AN) tissues. The tumour tissues were subdivided into three
groups according to the serum a-fetoprotein (AFP) levels of the individual patients (AFP<20, between 20e400 and>400 ng/ml). The box
plots show the median (horizontal bar), 25th and 75th percentiles and the whiskers of the graph show the largest and smallest values.
4 Liu AM, Yao T-J, Wang W, et al. BMJ Open 2012;2:e000825. doi:10.1136/bmjopen-2012-000825
Serum-based microRNA biomarkers for hepatocellular carcinoma
Foster City, California, USA). For the total RNA
extracted, 10 ng of RNA was subjected to the reverse
transcription (RT) reactions using TaqMan miRNA
Reverse Transcription Kit (Applied Biosystems),
according to the manufacturer’s recommendation. The
RT products were then diluted by combining 10 ml RT
product with 57.8 ml water. qPCR reactions were
performed in duplicate, in scaled-down 10 mL reaction
volumes containing 5 ml TaqMan 2X Universal PCR
Master Mix with No AmpErase UNG (Applied Biosys-
tems), 0.5 ml 20X miRNA-specific TaqMan probe and
5 ml diluted RT product (ie, 1:15 final dilution in the
qPCR reaction). The qPCR reactions were run in ABI
StepOnePlus real-time PCR system, and data were
collected and analysed with StepOne software (Applied
Biosystems).
For each of the TaqMan miRNA assays, we deter-
mined the limits of linear quantification and PCR effi-
ciency. We prepared a standard calibration curve by
a 10-fold dilution of single-stranded DNA oligonucleo-
tides corresponding to the mature miRNA sequences
(ranged from 368 to 3.731010 copies of RT input). The
limits of linear quantification of each of the assays were
determined with PCR efficiencies of 10068% and
linearities (Pearson’s correlation) >0.99. To ensure the
reliability of the data, values that were near or below the
limits of the linear quantification were removed and
excluded from further analyses. miRNA concentrations
were normalised to the total RNA input and expressed
as the number of copies per nanogram of RNA.
Statistical analysis
The statistical differences of miRNA levels between
tumour and adjacent non-tumour tissues were deter-
mined by paired t test with univariate p value at <0.001
and false-discovery rate <0.001. Clustering of the
differentially expressed miRNAs was performed with
centred correlation and average linkage. The differences
of serum miRNAs before and after surgery were studied
by Wilcoxon signed-rank test, and p value at <0.05 was
considered statistically significant. Logistic regression
analysis was performed to analyse various combinations
of miRNA markers. The receiver operating characteristic
(ROC) curve and the area under the curve (AUC) were
used to determine the feasibility of using serum miRNA
concentration as a diagnostic marker for defining HCC.
The Youden’s Index was used to identify the optimal
cut-off point.
RESULTS
Candidate miRNAs are highly expressed in AFP-low tumour
tissues
To generate a comprehensive set of miRNA expression
profiles for HCC, we analysed expressions of 220
miRNAs from 96 pairs of HCC tumour and adjacent
non-tumour tissues using real-time qPCR as described.15
Clustering analysis revealed that HCC and non-tumour
tissues expressed distinct patterns of miRNAs as shown
in the heat map (figure 2A). Furthermore, statistical
analysis using paired t test identified that 105 miRNAs
Figure 3 TaqMan quantitative
PCR assay of extracellular levels
of four candidate biomarkers,
miR-15b, miR-21, miR-130b and
miR-183, in culture medium
harvested from four hepatocellular
carcinoma cell lines (HepG2,
Hep3B, PLC/PRF/5 (PLC) and
MHCC-97H (97H)) and two
immortalised hepatocyte cell lines
(CL-48 and MIHA). The assays
were repeated at least twice in
different samples. The error bars
represent mean6SEM.
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were differentially expressed with false-discovery rate
<0.001.
Given the marked miRNA alteration in tumour tissues,
our next question is whether certain miRNAs could be
useful for detecting HCC cases, including those with low
serum AFP of <400 ng/ml. We identified the following
14 miRNAs upregulated in the AFP-low HCC subgroup:
miR-9, -9*, -15b, -21, -34c, -96, -130b, -183, -188, -196b,
-216, -224, -301 and -324-5p. Subsequently, we selected
those having high copy number (>100 copies/10 pg
input RNA) present in the tumour tissues. Consistently,
these six miRNAs (miR-15b, -21, -130b, -183, -224 and
-301) were highly expressed in all HCC samples of
varying serum AFP levels (figure 2B).
Detection of candidate miRNAs in HCC
culture supernatant
Our next selection criterion is whether the miRNAs can
be measured or detected in the culture supernatants
from a panel of HCC cell lines. We thus assayed by
qPCR the above selected miRNAs in culture media
conditioned with a panel of HCC cell lines, including
HepG2, Hep3B, PLC/PRF/5 and MHCC-97H. Two
immortalised human hepatocyte cell lines, CL-48 and
Figure 4 Declination of serum microRNA (miRNA) markers in patients with hepatocellular carcinoma (HCC) after surgery
treatment. Changes in serum levels of miR-15b, miR-21, miR-130b and miR-183 in patients with HCC (n¼15) before (pre-op) and
after (post-op) surgical removal of the tumours. Statistical differences were analysed using Wilcoxon signed-rank test. Table in the
lower panel indicates the median level of the individual miRNAs before and after surgery.
Table 2 Predictive performance of individual serum miRNAs and miRNA classifier (miR-15b and miR-130b) as biomarkers for
detection of HCC
Statistical parameters
Non-cancerous controls (n[59) versus HCCs (n[57)
miR-15b
(‡43.485
copies/ng)
miR-21
(‡73271.020
copies/ng)
miR-130b
(‡97.250
copies/ng)
miR-183
(‡40.100
copies/ng)
miR-15b +
miR-130b
(‡L0.6111
sum score)
Sensitivity (%) 98.25 89.47 87.72 57.89 98.25
Specificity (%) 15.25 71.19 81.36 69.49 91.53
False-positive rate (%) 84.75 28.81 18.64 30.51 8.47
False-negative rate (%) 1.75 10.53 12.28 42.11 1.75
Accuracy (%) 56.03 80.17 84.48 63.79 94.83
Positive predictive value (%) 52.83 75.00 81.97 64.71 91.80
Negative predictive value (%) 90 87.50 87.27 63.08 98.18
Positive likelihood ratio 1.159 3.105 4.705 1.898 11.593
Negative likelihood ratio 0.115 0.148 0.151 0.606 0.019
Youden’s Index 0.135 0.607 0.691 0.274 0.898
Area under the receiver
operating characteristic
0.485 0.865 0.913 0.661 0.981
HCC, hepatocellular carcinoma; microRNA, miRNA.
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Figure 5 Performance of the miR-15b and miR-130b classifier for detection of hepatocellular carcinoma (HCC) in an independent
cohort. (A) Receiver operating characteristic (ROC) curve analysis of the microRNA (miRNA) classifier over patients with HCC and
non-cancerous control subjects (healthy and chronic hepatitis B carriers). The miRNA classifier was derived from the logistic
regression model that composed of two miRNAs, that are, miR-15b and miR-130b. (B) Dot plots of the sum score of the logistic
Liu AM, Yao T-J, Wang W, et al. BMJ Open 2012;2:e000825. doi:10.1136/bmjopen-2012-000825 7
Serum-based microRNA biomarkers for hepatocellular carcinoma
MIHA, were included as controls. All the miRNAs could
be detected in the culture media, except miR-301 and
miR-224, whose concentrations were beyond the detec-
tion limits and thus were excluded from further anal-
yses. We found that miR-15b, miR-21, miR-183 and miR-
130b had generally higher copy numbers in the
medium of HCC cells when compared to CL-48 or
MIHA (figure 3).
Detection of miRNAs in serum samples from patients with
HCC pre- and post-surgery
To determine if the circulating miRNAs were derived
primarily from tumours, we measured their levels in
serum samples of 15 selected patients with HCC before
and after surgery treatment. In agreement with the tissue
data as stated above, miR-224 and miR-301 levels were
very low in the sera (data not shown). For the other four
miRNAs, there was a trend of reduction of miRNAs levels
after surgery. As shown in figure 4, the median copies of
miR-130b decreased significantly from 124.8 to 96.2
(p¼0.0158) and miR-183 from 153.3 to 95.2 (p¼0.0084).
We also observed reductions of miR-15b and miR-21
levels after surgery, although the declination was not
statistically significant. The median level of miR-15b was
reduced from 177.6 to 64.1 (p¼0.0637), whereas the
median level of miR-21 was decreased from 221 404.4 to
100 140.5 (p¼0.0648).
Circulating miR-15b and miR-130b classifier defines HCC
cases in an independent cohort
We next verified the discriminative power of these
miRNAs in identifying HCC cases in an independent
cohort of 30 healthy controls, 29 hepatitis B individuals
and 57 patients with HCC. The levels of the four miRNAs
in these serum samples were measured, and ROC anal-
ysis was performed on individual miRNAs. The cut-off of
each miRNA was selected with highest Youden’s Index.
Among the four miRNAs, miR-130b showed the highest
AUC of 0.913 (sensitivity of 87.7% and specificity of
81.4%) in separating the non-cancerous controls from
those with HCCs, whereas miR-15b gave the highest
sensitivity (98.3%), although its specificity (15.3%) was
only modest (table 2).
Recognising the limitations of individual tests, we
performed multivariate logistic regression analysis on
various combinations of themiRNAbiomarkers and found
that the combined miR-15b and miR-130b gave the best
performance. It could be a potential classifier for detecting
HCC, and the formula of the classifier is as follow:
2:4966 þ 0:0532 ðcopy number of miR130bÞ
 0:0210 ðcopy number of miR15bÞ:
The ROC curve of the classifier has an AUC of 0.981
(figure 5A). A sum score of the classifier at 0.61109 was
chosen as a cut-off, as it has the highest Youden’s Index
of 0.8977. At this cut-off, the classifier has enhanced
sensitivity of 98.3% and specificity of 91.5% (figure 5B)
when compared to the performance of individual
miRNAs.
We next tested if the classifier could successfully
differentiate a subset of patients with low serum AFP
from non-cancerous controls. Three subgroups were
defined: (1) HCCs with AFP >400 ng/ml (n¼11) and
non-cancerous controls (n¼59); (2) HCCs with AFP
between 20 and 400 ng/ml (n¼16) and non-cancerous
controls (n¼59); (3) HCCs with AFP <20 ng/ml (n¼30)
and non-cancerous controls (n¼59). We found that the
classifier could accurately distinguish subjects with HCC
from the controls with high sensitivity and specificity in
all cases (figure 5C). For the HCC subgroup with AFP
<20 ng/ml, the AUC of the classifier is 0.980, with
sensitivity of 96.7% and specificity of 91.5%.
Next, we evaluated the performance of miR-15b and
miR-130b classifier in detecting early-stage HCC cases. As
shown in figure 5D, the miRNA classifier could accu-
rately identify 97.8% (44 out of 45) HCC cases from both
tumour-node-metastasis stages I and II, whereas serum
AFP (cut-off level at 20 ng/ml) could only detect 48.9%
(22 out of 45) of the same cases. In short, the circulating
miR-15b and miR-130b is a classifier that outperforms
the serum AFP as tumour marker in detecting HCC.
DISCUSSION
The present study has developed an unprecedented
miRNA scoring system able to identify HCC cases that
could not be detected by the conventional AFP tumour
marker. Our in vitro studies also showed that the extra-
cellular miRNAs are good indicator of the miRNA
expression in cancer cells. These finding collectively
implicate the potential application of circulating
miRNAs as a non-invasive serological biomarker for solid
malignancy like HCC.
Our tumour biomarker discovery strategy is divided
into three phases: (1) Exploration phase: to identify
regression model in non-cancerous control subjects (Control) and patients with HCC (HCC). The sensitivity, specificity and
accuracy were calculated based on the cut-off at 0.611 that was determined by the Youden’s Index. (C) ROC curve analyses of
the miRNA classifier over control subjects (healthy and chronic hepatitis B individuals) and subgroup of patients with HCC with a-
fetoprotein (AFP) levels >400, between 20 and 400 or <20 ng/ml. The sensitivity, specificity, false-positive rate, false-negative rate
and accuracy at a cut-off of 0.611 were indicated below each ROC graph. (D) AFP and miRNA classifier (miR-15b and miR-130b)
were compared in HCC cases between early (I and II) and late (III and IV) stages. The cut-off values were marked by grey lines.
AUC, area under the curve.
[Continued]
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candidate markers through molecular profiling of
miRNAs in matched tumour and adjacent non-tumour
tissues samples from patients with HCC (n¼96). (2)
Selection/filtering phase: to select those miRNAs highly
expressed in both tumour tissues as well as in serum
samples. In addition, we used preoperative and post-
operative serum samples from the same patients with
HCC (n¼15) to further refine those miRNAs that were
likely derived from HCC tumours. After surgical removal
of the HCC tumours, serum levels of these miRNAs were
significantly reduced. (3) Cross-centre validation phase: to
validate the miRNA biomarkers in an independent
cohort (n¼116), including HCC cases, hepatitis B
carriers and non-malignant healthy controls from
geographically distant medical centre. Herein, our
findings showed that the combined miR-15b and miR-
130b is a robust classifier in detecting HCC cases and
outperforms AFP as tumour marker with high positive
predictive value.
Previous studies have suggested the potential use of
circulating miRNAs in the diagnosis of HCC.20 21 The
study by Qu et al 21 suggested that serum miR-16 could be
used as a second-line test when the serum AFP and other
markers are at normal levels. However, in our analysis, we
did not find miR-16 significantly differentially expressed
between tumour and adjacent normal tissues. Another
study using Solexa sequencing on pooled serum samples
identified miR-375 as a candidate biomarker for HBV-
positive HCC, which was further validated by TaqMan
miRNA qPCR assays.20 The majority of the HCC cases in
our cohort were also HBV-positive, but we did not select
miR-375 during our initial screen. This is because the
difference was not significant when comparing the HCC
tumours of low AFP level with the corresponding normal
samples. Nevertheless, we indeed found miR-375 has an
important role in regulating YAP oncogenic signalling
pathway in HCC.22 Further investigation is under way to
evaluate the application of miR-375 for identifying subtype
of HCC, for which the Hippo-YAP signaling is aberrantly
regulated.
Limited information of miR-15b is available in HCC,
and its molecular mechanisms and roles in pathogenesis
remain largely unknown. Consistent with the present
findings, miR-15b was recently shown to be overex-
pressed in HCC tumours,23 and it is in a pilot cross-
sectional, phase II biomarker study for Barrett’s
oesophagus progression.24 Recently, miR-15b has been
shown to be a direct transcriptional target of E2F and
may be involved in preventing replicative stress in
response to mitogenic signalling.25 On the other hand,
the oncogenic role of miR-130b in hepatocarcinogenesis
is prominent and is considered as a cancer stem cell
miRNA in HCC. First, it has been shown highly expressed
in CD133+ tumour-initiating cells in HCC, and trans-
duction of miR-130b into CD133-negative cells could
promote tumourigenesis and induce chemoresistance.26
Second, miR-130b directly targets a well-known tumour
suppressor, RUNX3, and regulates expression of pro-
apoptotic Bim, thereby enhancing cell viability.27 Despite
of these observations, it is still unknown if miR-15b and
miR-130b in circulation contribute to HCC development
and tumour progression.
Although the miRNA classifier gave a high positive
predictive value in our HCC cohort, there are several
limitations in this study. First, the classifier has yet to be
validated in other ethnic populations, such as Europe
and Japan in which hepatitis C virus is the major aeti-
ology of HCC. Second, the post-surgical serum samples
were in small sample size and varied at different time
points. It would be imperative to test more longitudinal
samples in order to justify the specific time or period
that the circulating miRNAs return to basal levels.
There are mounting evidences indicating that serum-
based miRNAs are useful as non-invasive biomarkers for
different cancer types.14 28e32 Today, circulating miRNAs
in serum have been reported as potential diagnostic
markers for B cell lymphoma,33 leukaemia,34 oesophageal
squamous cell carcinoma,35 as well as lung,36 breast,37
colon,38 gastric,39 pancreatic,40 prostate41 and ovarian42
cancers. A handful of studies showed that miRNAs could
be released into bloodstream via active secretion from
diseased tissues in forms of protein-bound complex43or
as membrane-bound vesicles (eg, exosomes).44 Because
of the high rate of proliferation and cell lysis in tumours,
non-specific passive release could also exist in cancer that
contribute to the abundance of miRNAs in the blood-
stream. Not only reflecting physiological and patholog-
ical changes, these circulating miRNAs could be
functional and correlated with tumour progression and
clinical outcomes.32 45 46 Most recently, miR-16, -21, -122
and -375 in serum were suggested as potential diagnostic
markers for HCC.20 21 47 Nevertheless, their diagnostic
performance has not been robustly validated in an inde-
pendent cohort. Our present findings demonstrate that
the circulating miR-15b and miR-130b hold promise as
valuable tumour markers for detecting HCC, in which
both the early-stage and low-AFP groups were covered
with high sensitivity and specificity. Early detection of
HCC could save many lives and enhance the quality of
life in patients suffering from this lethal malignancy.
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